This site is intended for health professionals only

Rivaroxaban supported by NICE


Oral rivaroxaban tablets have been recommended by the National 

Institute for Health and Clinical Excellence (NICE), the UK drug 

recommendation body, as a new treatment option for prevention of 

stroke and systemic embolism in patients with non-valvular atrial

fibrillation (AF) with one or more risk factors. 


The NICE recommendation gives eligible patients cared for by the 

UK health service with non-valvular AF in England and Wales 

access to rivaroxaban – the first one tablet per day, oral stroke

prevention medicine since the introduction of warfarin in the 1950s.


NICE estimates that almost half (46%) of AF patients who should be

receiving warfarin are not currently taking it. 



Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: